Reciprocal inhibition between TP63 and STAT1 regulates anti-tumor immune response through interferon-γ signaling in squamous cancer.

Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
20 Mar 2024
Historique:
received: 25 06 2023
accepted: 11 03 2024
medline: 21 3 2024
pubmed: 21 3 2024
entrez: 21 3 2024
Statut: epublish

Résumé

Squamous cell carcinomas (SCCs) are common and aggressive malignancies. Immune check point blockade (ICB) therapy using PD-1/PD-L1 antibodies has been approved in several types of advanced SCCs. However, low response rate and treatment resistance are common. Improving the efficacy of ICB therapy requires better understanding of the mechanism of immune evasion. Here, we identify that the SCC-master transcription factor TP63 suppresses interferon-γ (IFNγ) signaling. TP63 inhibition leads to increased CD8

Identifiants

DOI: 10.1038/s41467-024-46785-9 PMID: 38509096
pubmed: 38509096
doi: 10.1038/s41467-024-46785-9
pii: 10.1038/s41467-024-46785-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2484

Informations de copyright

© 2024. The Author(s).

Références

Jemal, A. et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J. Natl Cancer Inst. 105, 175–201 (2013).
pubmed: 23297039 pmcid: 3565628 doi: 10.1093/jnci/djs491
Sung, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 71, 209–249 (2021).
pubmed: 33538338 doi: 10.3322/caac.21660
Doki, Y. et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N. Engl. J. Med. 386, 449–462 (2022).
pubmed: 35108470 doi: 10.1056/NEJMoa2111380
Garon, E. B. et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N. Engl. J. Med. 372, 2018–2028 (2015).
pubmed: 25891174 doi: 10.1056/NEJMoa1501824
Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020–2031 (2019).
pubmed: 31562796 doi: 10.1056/NEJMoa1910231
Kirchhammer, N., Trefny, M. P., Auf der Maur, P., Laubli, H. & Zippelius, A. Combination cancer immunotherapies: emerging treatment strategies adapted to the tumor microenvironment. Sci. Transl. Med. 14, eabo3605 (2022).
pubmed: 36350989 doi: 10.1126/scitranslmed.abo3605
Liu, Z. et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 41, 181–195.e189 (2023).
pubmed: 36584672 doi: 10.1016/j.ccell.2022.12.004
Lu, Z. et al. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. BMJ 377, e068714 (2022).
pubmed: 35440464 pmcid: 9016493 doi: 10.1136/bmj-2021-068714
Sun, J. M. et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet 398, 759–771 (2021).
pubmed: 34454674 doi: 10.1016/S0140-6736(21)01234-4
Wang, Z. X. et al. Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial. Cancer Cell 40, 277–288.e273 (2022).
pubmed: 35245446 doi: 10.1016/j.ccell.2022.02.007
Wilke, H. et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 15, 1224–1235 (2014).
pubmed: 25240821 doi: 10.1016/S1470-2045(14)70420-6
Wolchok, J. D. et al. Overall survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).
pubmed: 28889792 pmcid: 5706778 doi: 10.1056/NEJMoa1709684
Mei, Z., Huang, J., Qiao, B. & Lam, A. K. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma. Int. J. Oral Sci. 12, 16 (2020).
pubmed: 32461587 pmcid: 7253444 doi: 10.1038/s41368-020-0084-8
Paz-Ares, L. et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N. Engl. J. Med. 379, 2040–2051 (2018).
pubmed: 30280635 doi: 10.1056/NEJMoa1810865
Zhang, J., Huang, D., Saw, P. E. & Song, E. Turning cold tumors hot: from molecular mechanisms to clinical applications. Trends Immunol. 43, 523–545 (2022).
pubmed: 35624021 doi: 10.1016/j.it.2022.04.010
Cillo, A. R. et al. Immune landscape of viral- and carcinogen-driven head and neck cancer. Immunity 52, 183–199.e189 (2020).
pubmed: 31924475 pmcid: 7201194 doi: 10.1016/j.immuni.2019.11.014
Dinh, H. Q. et al. Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment. Nat. Commun. 12, 7335 (2021).
pubmed: 34921160 pmcid: 8683407 doi: 10.1038/s41467-021-27599-5
Kurten, C. H. L. et al. Investigating immune and non-immune cell interactions in head and neck tumors by single-cell RNA sequencing. Nat. Commun. 12, 7338 (2021).
pubmed: 34921143 pmcid: 8683505 doi: 10.1038/s41467-021-27619-4
Yao, J. et al. Single-cell transcriptomic analysis in a mouse model deciphers cell transition states in the multistep development of esophageal cancer. Nat. Commun. 11, 3715 (2020).
pubmed: 32709844 pmcid: 7381637 doi: 10.1038/s41467-020-17492-y
Zhang, X. et al. Dissecting esophageal squamous-cell carcinoma ecosystem by single-cell transcriptomic analysis. Nat. Commun. 12, 5291 (2021).
pubmed: 34489433 pmcid: 8421382 doi: 10.1038/s41467-021-25539-x
Zheng, Y. et al. Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment. Nat. Commun. 11, 6268 (2020).
pubmed: 33293583 pmcid: 7722722 doi: 10.1038/s41467-020-20019-0
Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576–582 (2015).
doi: 10.1038/nature14129
Cancer Genome Atlas Research Networket al. Integrated genomic characterization of oesophageal carcinoma. Nature 541, 169–175 (2017).
doi: 10.1038/nature20805
Lin, D. C. et al. Genomic and molecular characterization of esophageal squamous cell carcinoma. Nat. Genet. 46, 467–473 (2014).
pubmed: 24686850 pmcid: 4070589 doi: 10.1038/ng.2935
Pickering, C. R. et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov. 3, 770–781 (2013).
pubmed: 23619168 doi: 10.1158/2159-8290.CD-12-0537
Watanabe, H. et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J. Clin. Invest. 124, 1636–1645 (2014).
pubmed: 24590290 pmcid: 3973117 doi: 10.1172/JCI71545
Jiang, Y. et al. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression. Nat. Commun. 9, 3619 (2018).
pubmed: 30190462 pmcid: 6127298 doi: 10.1038/s41467-018-06081-9
Jiang, Y. Y. et al. TP63, SOX2, and KLF5 establish a core regulatory circuitry that controls epigenetic and transcription patterns in esophageal squamous cell carcinoma cell lines. Gastroenterology 159, 1311–1327.e1319 (2020).
pubmed: 32619460 doi: 10.1053/j.gastro.2020.06.050
Xie, J. J. et al. Super-enhancer-driven long non-coding RNA LINC01503, regulated by TP63, is over-expressed and oncogenic in squamous cell carcinoma. Gastroenterology 154, 2137–2151.e2131 (2018).
pubmed: 29454790 doi: 10.1053/j.gastro.2018.02.018
Ivashkiv, L. B. IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy. Nat. Rev. Immunol. 18, 545–558 (2018).
pubmed: 29921905 pmcid: 6340644 doi: 10.1038/s41577-018-0029-z
Parker, B. S., Rautela, J. & Hertzog, P. J. Antitumour actions of interferons: implications for cancer therapy. Nat. Rev. Cancer 16, 131–144 (2016).
pubmed: 26911188 doi: 10.1038/nrc.2016.14
Jiang, Y. Y. et al. Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma. Gut 66, 1358–1368 (2017).
pubmed: 27196599 doi: 10.1136/gutjnl-2016-311818
Xue, R. et al. Liver tumour immune microenvironment subtypes and neutrophil heterogeneity. Nature 612, 141–147 (2022).
pubmed: 36352227 doi: 10.1038/s41586-022-05400-x
Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442–459.e429 (2020).
pubmed: 32302573 doi: 10.1016/j.cell.2020.03.048
Caushi, J. X. et al. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. Nature 596, 126–132 (2021).
pubmed: 34290408 pmcid: 8338555 doi: 10.1038/s41586-021-03752-4
Daniel, B. et al. Divergent clonal differentiation trajectories of T cell exhaustion. Nat. Immunol. 23, 1614–1627 (2022).
pubmed: 36289450 doi: 10.1038/s41590-022-01337-5
Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573–3587.e3529 (2021).
pubmed: 34062119 pmcid: 8238499 doi: 10.1016/j.cell.2021.04.048
Holling, T. M., Schooten, E., Langerak, A. W. & van den Elsen, P. J. Regulation of MHC class II expression in human T-cell malignancies. Blood 103, 1438–1444 (2004).
pubmed: 14563641 doi: 10.1182/blood-2003-05-1491
Burr, M. L. et al. An evolutionarily conserved function of polycomb silences the MHC class I antigen presentation pathway and enables immune evasion in cancer. Cancer Cell 36, 385–401.e388 (2019).
pubmed: 31564637 pmcid: 6876280 doi: 10.1016/j.ccell.2019.08.008
Villarino, A. V., Kanno, Y. & O’Shea, J. J. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat. Immunol. 18, 374–384 (2017).
pubmed: 28323260 doi: 10.1038/ni.3691
Sadzak, I. et al. Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain. Proc. Natl Acad. Sci. USA 105, 8944–8949 (2008).
pubmed: 18574148 pmcid: 2435588 doi: 10.1073/pnas.0801794105
Frank, D. A., Mahajan, S. & Ritz, J. Fludarabine-induced immunosuppression is associated with inhibition of STAT1 signaling. Nat. Med. 5, 444–447 (1999).
pubmed: 10202937 doi: 10.1038/7445
Glathar, A. R., Oyelakin, A., Gluck, C., Bard, J. & Sinha, S. p63 directs subtype-specific gene expression in hpv+ head and neck squamous cell carcinoma. Front. Oncol. 12, 879054 (2022).
pubmed: 35712470 pmcid: 9192977 doi: 10.3389/fonc.2022.879054
Borden, E. C. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. Nat. Rev. Drug Discov. 18, 219–234 (2019).
pubmed: 30679806 doi: 10.1038/s41573-018-0011-2
Gao, J. J. et al. Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397 (2016).
pubmed: 27667683 pmcid: 5088716 doi: 10.1016/j.cell.2016.08.069
Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19, 1189–1201 (2017).
pubmed: 28494868 pmcid: 6420824 doi: 10.1016/j.celrep.2017.04.031
Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
pubmed: 27903500 doi: 10.1158/2159-8290.CD-16-1223
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. New Engl. J. Med. 375, 819–829 (2016).
pubmed: 27433843 doi: 10.1056/NEJMoa1604958
Katlinski, K. V. et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31, 194–207 (2017).
pubmed: 28196594 pmcid: 5313042 doi: 10.1016/j.ccell.2017.01.004
Liao, W. T. et al. KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Cancer Cell 35, 559 (2019).
pubmed: 30905761 pmcid: 6467776 doi: 10.1016/j.ccell.2019.02.008
Bidwell, B. N. et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18, 1224–1231 (2012).
pubmed: 22820642 doi: 10.1038/nm.2830
Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med. 373, 123–135 (2015).
pubmed: 26028407 pmcid: 4681400 doi: 10.1056/NEJMoa1504627
Melino, G. p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 18, 1487–1499 (2011).
pubmed: 21760596 pmcid: 3178431 doi: 10.1038/cdd.2011.81
Steurer, S. et al. p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomark. Res. 9, 7 (2021).
pubmed: 33494829 pmcid: 7830855 doi: 10.1186/s40364-021-00260-5
Colombo, N. et al. Anti-tumor and immunomodulatory activity of intraperitoneal IFN-gamma in ovarian carcinoma patients with minimal residual tumor after chemotherapy. Int. J. Cancer 51, 42–46 (1992).
pubmed: 1563843 doi: 10.1002/ijc.2910510109
de La Salmoniere, P., Grob, J. J., Dreno, B., Delaunay, M. & Chastang, C. White blood cell count: a prognostic factor and possible subset indicator of optimal treatment with low-dose adjuvant interferon in primary melanoma. Clin. Cancer Res. 6, 4713–4718 (2000).
pubmed: 11156224
Hannesdottir, L. et al. Lapatinib and doxorubicin enhance the Stat1-dependent antitumor immune response. Eur. J. Immunol. 43, 2718–2729 (2013).
pubmed: 23843024 doi: 10.1002/eji.201242505
Stagg, J. et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc. Natl Acad. Sci. USA 108, 7142–7147 (2011).
pubmed: 21482773 pmcid: 3084100 doi: 10.1073/pnas.1016569108
Opitz, O. G. et al. A mouse model of human oral-esophageal cancer. J. Clin. Invest. 110, 761–769 (2002).
pubmed: 12235107 pmcid: 151126 doi: 10.1172/JCI0215324
Predina, J. D. et al. Neoadjuvant in situ gene-mediated cytotoxic immunotherapy improves postoperative outcomes in novel syngeneic esophageal carcinoma models. Cancer Gene Ther. 18, 871–883 (2011).
pubmed: 21869822 pmcid: 3215998 doi: 10.1038/cgt.2011.56
Judd, N. P. et al. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 72, 365–374 (2012).
pubmed: 22086849 doi: 10.1158/0008-5472.CAN-11-1831
Yuan, J. et al. Super-enhancers promote transcriptional dysregulation in nasopharyngeal carcinoma. Cancer Res. 77, 6614–6626 (2017).
pubmed: 28951465 pmcid: 6637769 doi: 10.1158/0008-5472.CAN-17-1143
Zheng, G. X. et al. Massively parallel digital transcriptional profiling of single cells. Nat. Commun. 8, 14049 (2017).
pubmed: 28091601 pmcid: 5241818 doi: 10.1038/ncomms14049
Stuart, T. et al. Comprehensive Integration of Single-Cell Data. Cell 177, 1888–1902.e1821 (2019).
pubmed: 31178118 pmcid: 6687398 doi: 10.1016/j.cell.2019.05.031
Liberzon, A. et al. The molecular signatures database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969 doi: 10.1016/j.cels.2015.12.004
Li, H. et al. The sequence alignment/map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
pubmed: 19505943 pmcid: 2723002 doi: 10.1093/bioinformatics/btp352
Liu, T. Use model-based Analysis of ChIP-Seq (MACS) to analyze short reads generated by sequencing protein-DNA interactions in embryonic stem cells. Methods Mol. Biol. 1150, 81–95 (2014).
pubmed: 24743991 doi: 10.1007/978-1-4939-0512-6_4
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 38, 576–589 (2010).
pubmed: 20513432 pmcid: 2898526 doi: 10.1016/j.molcel.2010.05.004

Auteurs

Yuan Jiang (Y)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
University of Science and Technology of China, Hefei, 230026, China.

Yueyuan Zheng (Y)

Clinical Big Data Research Center, Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China.
ORCID: 0000-0002-5692-8903

Yuan-Wei Zhang (YW)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.

Shuai Kong (S)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
University of Science and Technology of China, Hefei, 230026, China.

Jinxiu Dong (J)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.

Fei Wang (F)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
University of Science and Technology of China, Hefei, 230026, China.

Benjamin Ziman (B)

Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90033, USA.

Sigal Gery (S)

Department of Medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.

Jia-Jie Hao (JJ)

State Key Laboratory of Molecular Oncology, Center for Cancer Precision Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

Dan Zhou (D)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Institutes of Physical Science and Technology, Anhui University, Hefei, 230601, China.

Jianian Zhou (J)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
University of Science and Technology of China, Hefei, 230026, China.

Allen S Ho (AS)

Division of Otolaryngology-Head and Neck Surgery, Department of Surgery, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
ORCID: 0000-0001-5423-509X

Uttam K Sinha (UK)

Department of otolaryngology, Keck School of Medicine, University of Southern California, Los Angeles, CA, 90033, USA.

Jian Chen (J)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.

Shuo Zhang (S)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
University of Science and Technology of China, Hefei, 230026, China.

Chuntong Yin (C)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.

Dan-Dan Wei (DD)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China.
University of Science and Technology of China, Hefei, 230026, China.
Hefei Cancer Hospital, Chinese Academy of Sciences, Hefei, 230031, China.

Masaharu Hazawa (M)

Cell-Bionomics Research Unit, Innovative Integrated Bio-Research Core, Institute for Frontier Science Initiative, Kanazawa University, Kanazawa, Ishikawa, Japan.

Huaguang Pan (H)

Department of Thoracic Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.

Zhihao Lu (Z)

Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Institute, Beijing, 100142, China.

Wen-Qiang Wei (WQ)

Department of Cancer Epidemiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.
ORCID: 0000-0003-2078-9056

Ming-Rong Wang (MR)

State Key Laboratory of Molecular Oncology, Center for Cancer Precision Medicine, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, China.

H Phillip Koeffler (HP)

Department of Medicine, Samuel Oschin Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, 90048, USA.
ORCID: 0000-0001-5839-9913

De-Chen Lin (DC)

Center for Craniofacial Molecular Biology, Herman Ostrow School of Dentistry, and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, 90033, USA. dechenli@usc.edu.
ORCID: 0000-0002-1951-367X

Yan-Yi Jiang (YY)

Institute of Health and Medical Technology, Hefei Institutes of Physical Science, Chinese Academy of Sciences, Hefei, 230031, China. yanyij@cmpt.ac.cn.
University of Science and Technology of China, Hefei, 230026, China. yanyij@cmpt.ac.cn.
ORCID: 0000-0002-7432-8661

Classifications MeSH